Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Louisiana seeks California doctor’s extradition, testing the limits of shield laws - 24 Sound blocking Earphones for Prevalent Sound and Solace
- 3Insane Realities That Will Make You Reconsider How you might interpret History
- 46 Popular Men's Aromas On the planet
- 5All that You Really want to Be familiar with Dental Inserts Facilities
- Research highlights potential dangers of ultra-processed foods for women under 50 regarding precancerous polyps
- Remains of banker missing since 1999 found on California beach by family looking for seashells
- Kids who get 2-month vaccines on time 7 times more likely to receive MMR shot: Study
- A Manual for Pick High Evaluated Food Conveyance Administrations In Significant Urban communities For 2024
- 4 injured in suburban Philadelphia nursing home explosion file negligence lawsuit
- Air travelers face higher ticket prices as Iran war drives up oil prices
- Tesla Stock Hasn’t Looked This Cheap in a While
- Man Charged for Stealing ‘Incredibly Precious’ 286-Year-Old Violin, Worth More Than $200,000, from a Tavern
- 6 Web-based Course Stages for Successful Learning and Educating
